Mon panier

Bispecific Human BCMA & CD3E Bridging ELISA Kit

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
BIS-A001-96tests
$425.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Materials Provided

    ID
    Components
    Size
    BIS001-C01
    Pre-coated Human BCMA Protein Microplate
    1 plate (8×12 strips)
    BIS001-C02
    Anti-BCMA & CD3 Antibody Standard
    20 μg
    BIS001-C03
    Biotin-Human CD3E Protein
    20 μg
    BIS001-C04
    Streptavidin-HRP
    20 μg
    BIS001-C05
    10×Washing Buffer
    50 mL
    BIS001-C06
    2×Dilution Buffer
    50 mL
    BIS001-C07
    Substrate Solution
    12 mL
    BIS001-C08
    Stop Solution
    7 mL

  • Product Overview

    The kit is designed to analyze the ability of Bispecific Antibodies (BsAbs) to bridge BCMA (B-Cell Maturation Antigen, also known as Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)) and CD3 (cluster of differentiation 3) for screening and profiling applications. This assay kit can determine if an anti-BCMA-anti-CD3 bispecific antibody binds to both targets simultaneously and bridges BCMA to CD3.

  • Storage

    1. Store the unopened kit at 2-8°C upon receipt.

    2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.

    3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Typical Data 

    Please refer to DS document for the assay protocol.

     BCMA & CD3E TYPICAL DATA

    Detection of anti-BCMA & CD3 antibodies by Bridging ELISA Assay.
    Bispecific Human BCMA & CD3E Bridging ELISA Kit can specifically identify Anti-BCMA & CD3 Antibodies, with linear range of 0.010-0.317 nM (QC tested).

  •  BCMA & CD3E TYPICAL DATA

    The kit shows favorable lot-to-lot consistency, with the RSD of EC50 less than 25%.

Avis des utilisateurs
Publier un commentaire

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs